B-DIT Feasibility Study

计划入组 27 人 · 首次发布于 2024 年 6 月 24 日

Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke

计划入组 80 人 · 首次发布于 2022 年 5 月 5 日

Ixekizumab Diabetes Intervention Trial (I-DIT)

计划入组 127 人 · 首次发布于 2020 年 10 月 19 日

DIT-112

PMC-309

YD-309

Synendos Therapeutics AG

Switzerland

Ultimovacs ASA

Norway

Assiut University

Egypt

Osteosarcoma Pipeline 2026: HS-20093 Leads Phase III as Over 25 Companies Advance Novel Therapies

Aprogen's PMC-309 Shows Early Anticancer Activity in Phase 1 Trial, Advances to Higher Dose Testing

DeLLphi-309: Extended-Interval Tarlatamab Dosing Shows Comparable Activity in Relapsed SCLC